LENZ
LENZ Therapeutics, Inc.
$31.38
-2.02
(-6.05%)
| Exchange: | NASDAQ |
| Market Cap: | 883.228M |
| Shares Outstanding: | 8.297M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Biotechnology | |||||
| CEO: | Evert B. Schimmelpennink | |||||
| Full Time Employees: | 6 | |||||
| Address: |
|
|||||
| Website: | https://www.lenz-tx.com |
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Click to read more…
Revenue Segmentation
🔒 You are currently logged out
Income Statement
(* All numbers are in thousands)
🔒 You are currently logged out
Balance Sheet
(* All numbers are in thousands)
🔒 You are currently logged out
Cash Flow Statement
(* All numbers are in thousands)
🔒 You are currently logged out
Analyst Estimates
(* All numbers are in thousands)
